Scott Mendel

Scott Mendel is a declared insider at 4 companies (senior executive); the most frequent names are GenMark Diagnostics, Inc., Quanterix Corp and Akoya Biosciences, Inc. Over a trading history stretching from 21 January 2016 to 1 October 2026, the count stands at 72 filings.

In open-market terms, that means 2 purchases worth €191k on one side and 50 sales worth €2.3M on the other. The net balance comes to €2.1M on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 13 share grants and 6 option exercises.

The newest entry dates from 2 October 2026: a share grant of €13k, in Quanterix Corp. The clock since the last published purchase (12 June 2023) now reads 1,227 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.